These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255 [TBL] [Abstract][Full Text] [Related]
4. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation. Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164 [TBL] [Abstract][Full Text] [Related]
5. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease. A pilot study in ten patients. Herve P; Flesch M; Cahn JY; Racadot E; Plouvier E; Lamy B; Rozenbaum A; Noir A; Des Floris RL; Peters A Transplantation; 1985 Feb; 39(2):138-43. PubMed ID: 3881852 [TBL] [Abstract][Full Text] [Related]
6. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087 [TBL] [Abstract][Full Text] [Related]
7. Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. Remlinger K; Martin PJ; Hansen JA; Doney KC; Smith A; Deeg HJ; Sullivan K; Storb R; Thomas ED Hum Immunol; 1984 Jan; 9(1):21-35. PubMed ID: 6198309 [TBL] [Abstract][Full Text] [Related]
8. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Prentice HG; Blacklock HA; Janossy G; Bradstock KF; Skeggs D; Goldstein G; Hoffbrand AV Lancet; 1982 Mar; 1(8274):700-3. PubMed ID: 6122004 [TBL] [Abstract][Full Text] [Related]
9. Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trial. Beelen DW; Graeven U; Schulz G; Grosse-Wilde H; Doxiadis I; Schaefer UW; Quabeck K; Sayer H; Schmidt CG Onkologie; 1988 Feb; 11(1):56-8. PubMed ID: 3283628 [TBL] [Abstract][Full Text] [Related]
10. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study. Filipovich AH; McGlave P; Ramsay NK; Goldstein G; Kersey JH J Clin Immunol; 1982 Jul; 2(3 Suppl):154S-157S. PubMed ID: 6752174 [TBL] [Abstract][Full Text] [Related]
11. Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Gleixner B; Kolb HJ; Holler E; Liesenfeld S; Riedner C; Hiller E; Seeber C; Kempeni J; Möller A; Knabe H Bone Marrow Transplant; 1991 Aug; 8(2):93-8. PubMed ID: 1933064 [TBL] [Abstract][Full Text] [Related]
12. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease]. Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686 [TBL] [Abstract][Full Text] [Related]
13. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Anasetti C; Martin PJ; Storb R; Appelbaum FR; Beatty PG; Davis J; Doney K; Hill HF; Stewart P; Sullivan KM Transplantation; 1992 Nov; 54(5):844-51. PubMed ID: 1440852 [TBL] [Abstract][Full Text] [Related]
14. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Filipovich AH; McGlave PB; Ramsay NK; Goldstein G; Warkentin PI; Kesey JH Lancet; 1982 Jun; 1(8284):1266-9. PubMed ID: 6123018 [TBL] [Abstract][Full Text] [Related]
15. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150 [TBL] [Abstract][Full Text] [Related]